Lipids and diabetic renal disease

Current Diabetes Reports

Volumn 5, Issue 6, 2005, Pages 445-448

  Cooper, Mark E ^a   Jandeleit Dahm, Karin A M ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHEMOKINE; CYTOKINE; ENALAPRIL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA;

ATHEROSCLEROSIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DRUG MECHANISM; DYSLIPIDEMIA; FAT INTAKE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; REVIEW;

EID: 29644442097     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0053-9     Document Type: Review

References (45)

1. Grone HJ, Walli AK, Grone E, et al.: Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells. Kidney Int 1990, 37:1449-1459.
2. Takemura T, Yoshioka K, Aya N, et al.: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993, 43:918-927.
3. Grone HJ, Walli AK, Grone EF: The role of oxidatively modified lipoproteins in lipid nephropathy. Contrib Nephrol 1997, 120:160-175.
4. Lassila M, Jandeleit-Dahm K, Seah KK, et al.: Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2002, 16:363-373.
5. French SW, Yamanaka W, Ostwald R: Dietary induced glomerulosclerosis in the guinea pig. Arch Pathol 1967, 83:204-210.
6. Wellmann KF, Volk BW: Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits. II. Long-term studies. Lab Invest 1971, 24:144-155.
7. Peric-Golia L, Peric-Golia M: Aortic and renal lesions in hypercholesterolemic adult, male, virgin Sprague-Dawley rats. Atherosclerosis 1983, 46:57-65.
8. Kasiske BL, O'Donnell MP, Schmitz PG, et al.: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990, 37:880-891.
9. Bank N, Aynedjian HS: Role of thromboxane in impaired renal vasodilatation response to acetylcholine in hypercholesterolemic rats. J Clin Invest 1992, 89:1636-1642.
10. Zatz R, Dunn BR, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925-1930.
11. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999, 56:1627-1637.
12. Grone HJ, Hohbach J, Grone EF: Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl 1996, 54:S18-S22.
13. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2-15.
14. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988, 33:667-672.
15. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988, 62:367-374.
16. Jandeleit-Dahm K, Cao Z, Cox AJ, et al.: Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl 1999, 71:S31-336.
17. Park YS, Guijarro C, Kim Y, et al.: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998, 31:190-194.
18. Inman SR, Stowe NT, Cressman MD, et al.: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999, 317:215-221.
19. Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000, 11:80-87.
20. Blanco S, Vaquero M, Gomez-Guerrero C, et al.: Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 2005, 18:557-565.
21. Cooper ME, Mundel P, Boner G: Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 2002, 22:393-398.
22. O'Donnell MP, Kasiske BL, Kim Y, et al.: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993, 91:83-87.
23. Casey RG, Joyce M, Roche-Nagle G, et al.: Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 2005, 123:176-181.
24. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993, 22:196-201.
25. Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995, 26:99-107.
26. Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994, 45:S125-S131.
27. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995, 47:907-910.
28. Wirta OR, Pasternack AI, Mustonen JT, et al.: Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients. Nephrol Dial Transplant 1996, 11:449-456.
29. Viswanathan VV, Snehalatha C, Ramachandran A, Viswanathan M: Proteinuria in NIDDM in south India: analysis of predictive factors. Diabetes Res Clin Pract 1995, 28:41-46.
30. Oue T, Namba M, Nakajima H, et al.: Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients--a 10 year follow-up study. Diabetes Res Clin Pract 1999, 46:47-55.
31. Coppelli A, Giannarelli R, Vistoli F, et al.: The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 2005, 28:1366-1370.
32. Hommel E, Andersen P, Gall MA, et al.: Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992, 35:447-451.
33. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260-269.
34. Lam KS, Cheng IK, Janus ED, Pang RW: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995, 38:604-609.
35. Parving HH: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy [letter]. Diabetologia 1996, 39:367-368.
36. Tonolo G, Ciccarese M, Brizzi P, et al.: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997, 20:1891-1895.
37. Zhang A, Vertommen J, Van Gaal L, De Leeuw I: Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract 1995, 29:189-194.
38. Nielsen S, Schmitz O, Moller N, et al.: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993, 36:1079-1086.
39. Smulders YM, van Eeden AE, Stehouwer CD, et al.: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?. Eur J Clin Invest 1997, 27:997-1002.
40. Nagai T, Tomizawa T, Nakajima K, Mori M: Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 2000, 7:91-96.
41. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
42. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP: Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003, 19:615-617.
43. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
44. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310:356-360.
45. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.